MARKET WIREYahoo Finance • 18h ago
IMUNON Announces Strategic Sale of ThermoDox®Yahoo Finance report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
Why IMNN Stock surged +9.24% Today — RQD Quant Desk Flash
$0.91 +9.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.92
Imunon Inc. (IMNN) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $5.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on IMNN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is IMNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Imunon Inc. (NASDAQ: IMNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.91 (+9.24% 1D, market cap $5.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IMNN ranks #782 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does IMNN compare to PULM and GELS in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PULM (Pulmatrix Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M) and GELS (Gelteq Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M). Among the 5-stock peer group, IMNN leads on earnings multiple (N/A) while IMNN leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for IMNN?
▼
Per IMNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000749647), Imunon Inc. generated $0 in revenue, $14.5M in net income, and -$14.2M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.92 (+1.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-12.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMNN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY IMNN SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (29% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 38.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.07-5.6% Next Q
39
Q2 (-2Q)Grade E$1.01-12.9% Next Q
36
Q3 (-1Q)Grade E$0.88+3.4% Next Q
34
CurrentGrade E$0.91-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a IMNN Turnaround Squeeze
While IMNN currently carries a cautious 31/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.28) and Max Pain ($0.96) forces dealer call-delta covering toward $4.83.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMNN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IMNN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why IMNN Stock surged +9.24% Today — RQD Quant Desk Flash
Imunon Inc. (IMNN) surged +9.24% to $0.91, trading at 3% of its 52-week range ($0.81 – $4.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.81 – $4.6) with RSI-14 at 38.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.91 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live IMNN Headlines & Catalysts
MARKET WIRETradingView • 21h ago
Imunon, Inc. Estimates – NASDAQ:IMNNTradingView report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A brain cancer drug deal depends on VoxelDox's planned $2.5 million financingStock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
IMUNON to Participate in Upcoming Investor ConferencesGlobeNewswire report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A treatment for advanced ovarian cancer will feature in IMUNON's Nov. 12 updateStock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine Media • 1d ago
Imunon Transfers ThermoDox Assets to VoxelDox Therapeutics in Equity and Milestone AgreementKalkine Media report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Stock replaces part of base salary in Imunon (IMNN) medical chief’s 1,092-share award.Stock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
At $1.08 a share, Imunon (IMNN) grants its medical chief 1,249 shares in place of cash salary.Stock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 21h ago
IMUNON to Hold Third Quarter 2026 Financial Results and Business Update Conference Call on Thursday, November 12, 2026LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference
MARKET WIREChartMill • 6d ago
Top U.S. Gainers and Losers for Oct. 27, 2026 SessionOct. 27, 2026 U.S. top movers: BRAI led gainers at 73.58%, while DVLT led losers at -49.02%, ranked by percentage change.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMNN)
- ✓Walkthrough of IMNN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
IMNN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -67.50%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.83H $0.91L $0.83C $0.91VOL 132.5K
RES: $1.40SUP: $0.78SMA50: $1.28SMA200: $2.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
IMNN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on IMNN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for IMNN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IMNN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMNN)
Health Care Rank #782 of 1016
⚔️ PULM vs IMNN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (IMNN vs. PULM, GELS, ADXN, PCSA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Imunon Inc. (IMNN) ranks #782 by composite RQD confidence (31/100, grade E) and #942 by equity capitalization ($5.1M). Within this direct 5-issuer industry benchmark cohort, IMNN leads on earnings valuation at N/A trailing P/E, while IMNN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with IMNN at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IMNN
ACTIVE
Imunon Inc. | E | 31/100 | — | — | -35.0% | +9.24% | $5.1M | Benchmark Subject |
| PULM Pulmatrix Inc. | D- | 36/100 | — | — | -35.0% | -1.06% | $5.1M | /pulm-vs-imnn → |
| GELS Gelteq Limited | D+ | 54/100 | — | — | — | -3.14% | $5.2M | /gels-vs-imnn → |
| ADXN Addex Therapeutics Ltd | D | 48/100 | — | — | — | +5.46% | $5.3M | /adxn-vs-imnn → |
| PCSA Processa Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | 0.00% | $5.3M | /pcsa-vs-imnn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000749647In its most recent audited fiscal period (FY2025, filed 2025-12-31), Imunon Inc. (IMNN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $14.5M, operating cash flow of -$13.9M, and free cash flow of -$14.2M (+24.9% YoY). On the balance sheet, IMNN closed FY2025 with $12.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $14.5M | -$13.9M | -$14.2M | $12.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$18.6M | -$18.9M | -$18.9M | $9.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$19.5M | -$19.0M | -$19.0M | — | — |
3. IMNN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs IMNN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Imunon Inc. (NASDAQ: IMNN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.91 (+9.24% 1D, market cap $5.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, IMNN ranks #782 in composite RQD confidence.
How does IMNN compare to PULM and GELS in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMNN carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PULM (Pulmatrix Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.1M) and GELS (Gelteq Limited) posts a D+ grade (54/100 RQD, P/E N/A, ROIC —, cap $5.2M). Among the 5-stock peer group, IMNN leads on earnings multiple (N/A) while IMNN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for IMNN?
Per IMNN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000749647), Imunon Inc. generated $0 in revenue, $14.5M in net income, and -$14.2M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is IMNN trading relative to its 50-day, 200-day, and 52-week technical levels?
IMNN last traded at $0.91 (+9.24% on volume of 132,520 shares), positioning the stock -28.91% below its 50-day simple moving average ($1.28) and -58.82% below its 200-day simple moving average ($2.21). Across its 52-week range of $0.81 to $4.60, IMNN sits at the 2.6% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.02).
IMNN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is IMNN stock moving today?
Why IMNN Stock surged +9.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
IMNN — Imunon Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:53:28Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, IMNN scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine (4 / 20): ROIC of -35% and an FCF yield of 0%. The cash-generation pillar is nearly exhausted, reflecting negative operating income in each reported year.
- Whale 13F Flow (3 / 20): Institutional accumulation and options positioning score is weak; no holder-level detail is supplied in the source data to explain the score further.
- Insider Conviction (5 / 20): SEC Form 4 and Congressional PTR cluster flow scores low; the source data contains no insider or congressional trade detail.
- Macro Regime Fit (9 / 20): Beta of 1.0 and sector sensitivity give a middling-to-weak macro fit.
- Forensic Balance Sheet (10 / 20): Altman Z of 2.5, Piotroski F of 3/9, and Debt/Equity of 0.5 indicate a balance sheet with limited forensic strength.
For a prospective investor, the upside case rests almost entirely on a turnaround in operating cash generation, which the source data does not show. The valuation tradeoff is stark: a $4.7M market cap against negative operating income and negative free cash flow leaves little margin for error. A $0.83 share price sitting near the bottom of its $0.81 – $4.67 52-week range reflects that pressure. Second-order risk includes dilution or financing needs, though the source data does not quantify any financing plan beyond the news items noted below. The composite RQD rating frames the stock as high-risk on the evidence supplied.
Business
Imunon Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company is classified in that sector and industry. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M in each of FY 2023, FY 2024, and FY 2025. Revenue-generating activity is not available in source data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-14.7M | $14.5M | N/A | $-14.2M | $8.8M | N/A |
| FY 2024 | $0.0M | $-19.1M | $-18.6M | N/A | $-18.9M | $5.9M | N/A |
| FY 2023 | $0.0M | $-21.0M | $-19.5M | N/A | $-19.0M | N/A | N/A |
Per the SEC financials, operating income was negative in all three periods, and FCF was negative in all three. FY 2025 net income of $14.5M diverges sharply from its negative operating income; the source data does not explain the reconciling items. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Gross, operating, and net margins are all reported as 0%, consistent with zero revenue.
Recent Catalysts & News Wire Analysis
Per the recent news feed, all six items are flagged YELLOW with the impact label MARKET WIRE:
- Strategic sale of ThermoDox® (headline per Yahoo Finance): a transaction involving a core asset, with terms not detailed in the source data.
- Estimates report (per TradingView): a consensus-estimates-style item, without figures supplied.
- Planned $2.5 million financing for VoxelDox (per Stock Titan): a brain-cancer drug deal is described as dependent on this financing. This is a key risk watch item.
- Participation in upcoming investor conferences (per GlobeNewswire).
- Advanced ovarian cancer treatment update scheduled for Nov. 12 (per Stock Titan): a potential near-term catalyst.
- Transfer of ThermoDox assets to VoxelDox Therapeutics in an equity and milestone agreement (per Kalkine Media): indicates equity-based consideration and milestone-linked economics.
The Butterfly Supply-Chain Graph reports no supply chain (supply_chain: NONE), no butterfly links, and no proprietary signals.
Open Questions
- What is the source of the FY 2025 net income of $14.5M given operating income of $-14.7M?
- Does the planned $2.5 million VoxelDox financing close, and on what terms?
- What are the terms and proceeds of the ThermoDox sale and asset transfer?
- What is the cash runway given $8.8M of reported cash against negative FCF of $-14.2M in FY 2025?
- What is the debt profile, since reported debt is N/A in every period?
IMNN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Imunon Inc. (IMNN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 18h ago
IMUNON Announces Strategic Sale of ThermoDox® Yahoo Finance report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 21h ago
Imunon, Inc. Estimates – NASDAQ:IMNN TradingView report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A brain cancer drug deal depends on VoxelDox's planned $2.5 million financing Stock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
IMUNON to Participate in Upcoming Investor Conferences GlobeNewswire report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A treatment for advanced ovarian cancer will feature in IMUNON's Nov. 12 update Stock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine Media • 1d ago
Imunon Transfers ThermoDox Assets to VoxelDox Therapeutics in Equity and Milestone Agreement Kalkine Media report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Stock replaces part of base salary in Imunon (IMNN) medical chief’s 1,092-share award. Stock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
At $1.08 a share, Imunon (IMNN) grants its medical chief 1,249 shares in place of cash salary. Stock Titan report covering Imunon Inc. (IMNN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
IMNN Bull vs. Bear Conversation Board — What's Your Call at $0.91?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IMNN 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.73 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is IMNN (E • RQD 31/100) a Buy at $0.83?
Welcome to the IMNN (Imunon Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.66 (-20.5%)
Spot @ $0.83 Pump the brakes on IMNN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on IMNN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Imunon Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.06 (+27.7%)
Spot @ $0.83 IMNN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on IMNN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.83 (52-wk range $0.81 - $4.67), any beat on forward guidance forces shorts and underweight funds to chase.